Methotrexate use and alcohol

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Price, S ^a   James, C ^b   Deighton, C ^c  

^a HAYWOOD HOSPITAL   (United Kingdom)

^b Library and Knowledge Service   (United Kingdom)

^c ROYAL DERBY HOSPITAL   (United Kingdom)

Author keywords

Alcohol; Alcohol consumption; Ethanol; Methotrexate; Methotrexate toxicity; Psoriatic arthritis and alcoholic beverages; Rheumatoid arthritis

Indexed keywords

ALCOHOL; METHOTREXATE; AMINOTRANSFERASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG MONITORING; DRUG USE; HISTOPATHOLOGY; HUMAN; LEUKEMIA; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; LOW DRUG DOSE; NONALCOHOLIC FATTY LIVER; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK FACTOR; SELF REPORT; SYSTEMATIC REVIEW (TOPIC); CLINICAL PRACTICE; MEDICAL SOCIETY; PSORIASIS; RISK ASSESSMENT; SYSTEMATIC REVIEW;

ALCOHOL DRINKING; ANTIRHEUMATIC AGENTS; DRUG-INDUCED LIVER INJURY; EVIDENCE-BASED MEDICINE; HUMANS; LIVER DISEASES, ALCOHOLIC; METHOTREXATE; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 78650571971     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. RAJAKULENDRAN S, GADSBY K, DEIGHTON C: Rheumatoid arthritis, alcohol, leflunomide and methotrexate. Can changes to the BSR guidelines for leflunomide and methotrexate on alcohol consumption be justified? Musculoskeletal Care 2008;6:233-45.
2. TSUKAMOTO H, MACHIDA K, DYNNYK A, MKRTCHYAN H: "Second hit" models of alcoholic liver disease. Semin Liver Dis 2009;29:178-87.
3. COLSKY J, GREENSPAN EM, WARREN TN: Hepatic fibrosis in children with acute leukemia after therapy with folic acid antagonists. AMA Arch Pathol 1955;59:198-206.
4. COE RO, BULL FE: Cirrhosis associated with methotrexate treatment of psoriasis. JAMA 1968;206:1515-20.
5. EPSTEIN EH Jr, CROFT JD Jr: Cirrhosis following methotrexate administration for psoriasis. Arch Dermatol 1969;100:531-4.
6. MULLER SA, FARROW GM, MARTALOCK DL: Cirrhosis caused by methotrexate in the treatment of psoriasis. Arch Dermatol 1969;100:523-30.
7. ZACHARIAE H: Alcohol interactions with drugs and its effect on the treatment of skin diseases. Clin Dermatol 1999;17:443-5.
8. WHITING-O'KEEFE QE, FYE KH, SACK KD: Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991;90:711-6.
9. TILLING L, TOWNSEND S, DAVID J: Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 2006;26:55-62.
10. LINDSAY K, GOUGH A: Psoriatic arthritis, methotrexate and the liver-are rheumatologists putting their patients at risk? Rheumatology (Oxford) 2008;47:939-41.
11. GISONDI P, TARGHER G, ZOPPINIG, GIROLOMONI G: Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009;51:758-64.
12. WEINSTEIN G, ROENIGK H, MAIBACH H et al.: Psoriasis-liver-methotrexate interactions. Arch Dermatol 1973;108:36-42
13. NYFORS A: Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics. Dan Med Bull 1978;25:208-11.
14. ROBINSON JK, BAUGHMAN RD, AUERBACH R, CIMIS RJ: Methotrexate hepatotoxicity in psoriasis. Consideration of liver biopsies at regular intervals. Arch Dermatol 1980;116:413-5.
15. ROSENBERG P, URWITZ H, JOHANNESSON A et al.: Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007;46:1111-8.
16. AITHAL GP, HAUGK B, DAS S, CARD T, BURT AD, RECORD CO: Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment Pharmacol Ther 2004;19:391-9.
17. MALATJALIAN DA, ROSS JB, WILLIAMS CN, COLWELL SJ, EASTWOOD BJ: Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long-term follow-up. Can J Gastroenterol 1996;10:369-75.
18. KREMER JM, LEE RG, TOLMAN KG: Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989;32:121-7.
19. CHANDRAN G, AHERN MJ, HALL PD et al.: Cirrhosis in patients with rheumatoid arthritis receiving low dose methotrexate. Br J Rheumatol 1994;33:981-4.
20. SUZUKI Y, UEHARA R, TAJIMA C et al.: Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid. Scand J Rheumatol 1999;28:273-81.
21. WEST SG: Methotrexate hepatotoxicity. Rheum Dis Clin North Am 1997;23:883-915.
22. PHILLIPS CA, CERA PJ, MANGAN TF, NEWMAN ED: Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. J Rheumatol 1992;19:229-33.
23. ERICKSON AR, REDDY V, VOGELGESANG SA, WEST SG: Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum 1995;38:1115-9.
24. Electronic Medicines Compendium (internet). UK: The Summary of Product Characteristics, Methotrexate 2.5mg (updated 2010 April 21) Available from http://www.medicines.org.uk/EMC/medicine/22954/SPC/Me thotrexate+2.5mg+Tablets
25. VISSER K, KATCHAMART W, LOZA E et al.: Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-93.
26. AMERICAN COLLEGE OF RHEUMATOLOGY AD HOC COMMITTEE ON CLINICAL GUIDELINES: Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996;39:723-31.